437 results on '"Sauna, Zuben E."'
Search Results
2. Application of machine learning approaches for predicting hemophilia A severity
3. Endotoxin contamination in commercially available Cas9 proteins potentially induces T-cell mediated responses
4. Emerging approaches to induce immune tolerance to therapeutic proteins
5. A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII
6. Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus
7. Structural, functional, and immunogenicity implications of F9 gene recoding
8. A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA’s Benefit-Risk Framework
9. A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection
10. Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding
11. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation
12. Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine
13. Secondary failure: immune responses to approved protein therapeutics
14. Quantitative HLA‐class‐II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A
15. Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4+ T-cells
16. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue
17. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation.
18. The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity
19. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins
20. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.
21. Modified aptamers as reagents to characterize recombinant human erythropoietin products
22. Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
23. Archaeal and bacteriophage derived Cas proteins demonstrate memory T cell response in humans
24. Artificial Intelligence (AI) based approach for identifying biomarkers associated with neutralizing antidrug antibodies to Factor VIII used in Hemophilia A treatment
25. AptaCluster – A Method to Cluster HT-SELEX Aptamer Pools and Lessons from Its Application
26. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity
27. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity
28. The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics
29. Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
30. Higher-Order Structure and Protein Aggregate Characterization of Protein Therapeutics: Perspectives from Good Manufacturing Practices and Regulatory Guidance
31. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools
32. Summary of a Public FDA Workshop: Model Informed Drug Development Approaches for Immunogenicity Assessments
33. A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity
34. Summary of a Public FDA Workshop: Model Informed Drug Development Approaches for Immunogenicity Assessments.
35. Endotoxin contamination in commercially available Cas9 proteins potentially induces T-cell mediated responses
36. Mathematical model of a personalized neoantigen cancer vaccine and the human immune system
37. Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
38. What can be done with science education in Indian universities? An attempt at a synthesis
39. Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family
40. HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset
41. Genomics and the mechanism of P-glycoprotein (ABCB1)
42. Mathematical Model of a Personalized Neoantigen Cancer Vaccine and the Human Immune System: Evaluation of Efficacy
43. P-glycoprotein: from genomics to mechanism
44. The Mechanism of Action of Multidrug-Resistance-Linked P-Glycoprotein
45. The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding
46. Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1)
47. Silent (Synonymous) SNPs: Should We Care About Them?
48. Identification of sequence–structure RNA binding motifs for SELEX-derived aptamers
49. Editorial: Immunogenicity of Proteins Used as Therapeutics
50. Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.